GC/MS and LC/MS Metabolomic Analysis of Gefitinib in Liver Cancer
Biomedical Chromatography · 2026-06 · 40 (6)
DOI: 10.1002/bmc.70470 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 29.04.2026. Verfasst von Dan Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Gefitinib, Liver Neoplasms, Gas Chromatography-Mass Spectrometry, Metabolomics. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, Naval Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinoma, the third leading cause of cancer‐related deaths globally, presents a critical public health burden in China due to its high incidence and mortality. While targeted therapies and immunotherapies have improved survival in advanced HCC, drug resistance remains a major therapeutic challenge. Recent studies suggest that gefitinib, an EGFR inhibitor, overcomes lenvatinib resistance, yet its mechanistic underpinnings are incompletely understood. To investigate gefitinib's metabolic effects in HCC, we conducted untargeted metabolomic profiling using two separate platforms: gas chromatography–mass spectrometry (GC–MS) and liquid chromatography–mass spectrometry (LC–MS) with both hydrophilic interaction liquid chromatography (HILIC) and reversed‐phase modes. Raw data were processed by Mass Hunter, normalized with internal standards, and analyzed via SIMCA for pattern recognition. Principal component analysis (PCA) of quality control samples and experimental groups ( n = 6 each) confirmed system stability and clear inter‐group separation. Orthogonal projections to latent structures discriminant analysis models were validated by 200 permutation tests. Analysis identified 42 metabolites with VIP > 1, of which 25 showed significant alterations ( p < 0.05) post‐gefitinib treatment. KEGG/RaMP‐DB enrichment revealed perturbations in four key pathways: arginine‐proline metabolism, nitrogen metabolism, branched‐chain amino acid biosynthesis, and taurine metabolism. These results delineate gefitinib‐induced metabolic reprogramming in HCC cells, providing a foundation for targeting metabolic vulnerabilities to overcome therapy resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Naval Medical University, Shanghai, China.
- Department of Pharmacy, Third Affiliated Hospital of Naval Medical University, Shanghai, China.
- Basic Medical College, Naval Medical University, Shanghai, China.
- Center of Reproductive Medicine, First Affiliated Hospital of Naval Medical University, Shanghai, China.
ORCID-Profile: DongYao Wang, Leilei Bao, Diya Lv
Förderung
- Science and Technology Commission of Shanghai Municipality
- Naval Medical University
- National Natural Science Foundation of China
Zitieren
APA
Li, D., Zhang, Y., Chen, S., Zhang, L., Lv, Y., Wang, D., Bao, L., & Lv, D. (2026). GC/MS and LC/MS Metabolomic Analysis of Gefitinib in Liver Cancer. Biomedical Chromatography, 40(6). https://doi.org/10.1002/bmc.70470
Vancouver
Li D, Zhang Y, Chen S, Zhang L, Lv Y, Wang D, et al. GC/MS and LC/MS Metabolomic Analysis of Gefitinib in Liver Cancer. Biomedical Chromatography. 2026;40(6). doi:10.1002/bmc.70470
BibTeX
@article{Li2026,
author = {Li, Dan and Zhang, Yixin and Chen, Shitao and Zhang, Linfeng and Lv, Yan and Wang, DongYao and Bao, Leilei and Lv, Diya},
title = {GC/MS and LC/MS Metabolomic Analysis of Gefitinib in Liver Cancer},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {6},
doi = {10.1002/bmc.70470}
}
EUVIMED